[Tubulointerstitial nephritis and uveitis (TINU syndrome) - comorbidity and complications in four patients].
BACKGROUND
TINU syndrome probably is a frequently overlooked disease where uveitis occurs in association with acute tubulointerstitial nephritis. Diagnostic criteria have been published recently.


METHODS
In this retrospective case series the charts of four consecutive patients with TINU syndrome (follow-up 36, 23, 17, and 12 months, respectively) were analysed, including comorbidity and complications, and the literature was reviewed.


RESULTS
Two patients were treated with methotrexate or ciclosporin A and mycophenolate mofetil. In one patient autoimmune thyroiditis was known. During the follow-up, symptoms indicative of rheumatoid arthritis were observed. Because of her uveitis she required methotrexate therapy. Three patients were obese (mean BMI 32.2 kg/m (2)). Ocular complications were posterior synechiae (two patients) and papillary and macular oedema (three patients). One patient developed cerebrospinal hypertension under ciclosporin A treatment which resolved after discontinuation of therapy.


CONCLUSIONS
Patients with definite TINU syndrome frequently suffer from other diseases and associated immune phenomena. The course of the disease can vary considerably. Complications do occur, despite overall good prognosis. Regional and systemic steroids may be sufficient; frequently steroid sparing immunosuppressives are necessary at least temporarily. Patients with this multiorgan disease do need to be followed by a paediatrician or a medical specialist.
Hudde
Tobias
T
Universitätsaugenklinik Essen, Abteilung Erkrankungen des vorderen Augenabschnitts, Germany. tobias.hudde@uni-essen.de
Heinz
Carsten
C
Neudorf
Ulrich
U
Hoeft
Sabine
S
Heiligenhaus
Arnd
A
Steuhl
Klaus-Peter
KP
D000293:Adolescent; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000188:drug therapy; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D009395:Nephritis, Interstitial / Q000175:diagnosis* / Q000188:drug therapy; D010348:Patient Care Team; D013577:Syndrome; D013967:Thyroiditis, Autoimmune / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome; D014605:Uveitis / Q000175:diagnosis* / Q000188:drug therapy
D016572:Cyclosporine; D009173:Mycophenolic Acid; D008727:Methotrexate